Jump to content

Panel Discussions on Molecular Markers in Advanced Lung Canc


Recommended Posts

Guest LCSC Info
Posted

Panel Discussions on Molecular Markers in Advanced Lung Cancer: Check them out!

May 4th, 2012 - by Dr. Jack West

http://blog.lungevity.org/2012/05/04/pa ... -them-out/

Here are a couple of additional installments from our special two hour webinar on molecular markers in advanced NSCLC, broadcast from the Santa Monica Targeted Therapies in Lung Cancer conference and featuring four great panelists who joined me that day:

Drs. Charlie Rudin, Johns Hopkins University

Dr. Alice Shaw, Massachusetts General Hospital

Dr. David Spigel, Sarah Cannon Cancer Center

Dr. Glen Goss, University of Ottawa, and head of NCI-Canada’s Lung Cancer Committee

Part three of our program includes some debate on the merits of uniform vs. more selective testing of “druggable” targets, as well as a discussion of whether to favor simultaneous testing for molecular targets vs. a sequential, stepwise approach (because the key relevant targets are mutually exclusive). We also review the challenge of delays in treatment that can emerge as a byproduct of weeks of up front testing.

At the link above you’ll find the audio and video versions of the podcast, along with the transcript and figures for this activity.

Molecular Targets PD Pt 3 Video Podcast

Molecular Targets PD Pt 3 Audio Podcast

Molecular Targets PD Pt 3 Transcript

Molecular Targets PD Pt 3 Figures

The fourth part continued with an animated discussion of the pros and cons of incorporating more widespread molecular testing into broad clinical practice.

Click the link above for the audio and video versions of the 4th podcast, as well as the transcript (there aren’t any particularly relevant figures to go with this one):

Molecular Targets PD Pt 4 Video Podcast

Molecular Targets PD Pt 4 Audio Podcast

Molecular Targets PD Pt 4 Transcript

The upcoming segment (cleverly titled “Part 5″) will feature a presentation by Dr. Spigel on the process of incorporating molecular testing into new models for conducting clinical trials in lung cancer.

I hope these podcasts are interesting and helpful!

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.